Gemcitabine을 사용한 폐암환자에서 발생한 용혈성 요독증후군 1예 = A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine

다국어 초록 (Multilingual Abstract)

Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.

참고문헌 (Reference)

1 Ruggenenti P, "Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura" 60 : 831-846, 2001

2 Saif MW, "Thrombotic microangiopathy associated with gemcitabine: rare but real" 8 : 257-260, 2009

3 Flombaum CD, "Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine" 33 : 555-562,

4 Moake JL, "Thrombotic microangiopathies" 347 : 589-600, 2002

5 Bharthuar A, "Rituximab-based therapy for gemcitabine- induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report" 64 : 177-181, 2009

6 Werner TL, "Management of cancer-associated thrombotic microangiopathy: what is the right approach?" 82 : 295-298, 2007

7 Gore EM, "Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?" 4 : 209-214, 2009

8 Saif MW, "Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature" 6 : 369-374, 2005

9 Blackall DP, "Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation" 121 Suppl : 81-88, 2004

10 Caprioli J, "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome" 108 : 1267-1279, 2006

11 Zupancic M, "Gemcitabine-associated thrombotic thrombocytopenic purpura" 8 : 634-641, 2007

12 Licciardello JT, "Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin- based chemotherapy" 42 : 296-300, 1985

13 Duperray A, "Effect of mitomycin C on prostacyclin synthesis by human endothelial cells" 37 : 4753-4757, 1988

14 Fakhouri F, "Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?" 3 : 679-687, 2007

15 Walker RW, "Carboplatin-associated thrombotic microangiopathic hemolytic anemia" 64 : 1017-1020, 1989

16 Porta C, "Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production" 74 : 570-574, 1999

17 Oberic L, "Cancer awareness in atypical thrombotic microangiopathies" 14 : 769-779, 2009

18 Loirat C, "Atypical hemolytic uremic syndrome" 6 : 60-, 2011

19 Tsai HM, "Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura" 14 : 1072-1081, 2003

20 Fung MC, "A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy" 85 : 2023-2032, 1999